Paradigm Biocapital Advisors LP Immatics N.V. Transaction History
Paradigm Biocapital Advisors LP
- $1.95 Billion
- Q1 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Immatics N.V. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 1,907,108 shares of IMTX stock, worth $11.6 Million. This represents 0.44% of its overall portfolio holdings.
Number of Shares
1,907,108
Previous 5,414,409
64.78%
Holding current value
$11.6 Million
Previous $38.5 Million
77.66%
% of portfolio
0.44%
Previous 1.47%
Shares
8 transactions
Others Institutions Holding IMTX
# of Institutions
82Shares Held
91.5MCall Options Held
201KPut Options Held
109K-
T. Rowe Price Investment Management, Inc. Baltimore, MD14.7MShares$89.5 Million0.04% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$57.2 Million1.77% of portfolio
-
Suvretta Capital Management, LLC New York, NY9.14MShares$55.7 Million1.8% of portfolio
-
Wellington Management Group LLP Boston, MA8.58MShares$52.4 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY7.28MShares$44.4 Million0.39% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $465M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...